NCI-MATCH arms fall short in ASCO abstracts

Three arms of NCI’s Molecular Analysis for Therapy Choice (NCI-MATCH) tissue agnostic basket trial will report overall response rates (ORR) below 10% at the American Society of Clinical Oncology (ASCO) meeting in Chicago, according to abstracts released ahead of the meeting.

NCI-MATCH is an open-label, U.S. Phase II signal-seeking study that assigns patients with solid tumors, lymphomas or multiple myeloma to treatment arms according to molecular alterations in their cancers. According to NCI's website, treatments "will be considered promising if at least 16% of the patients in an arm have tumor shrinkage,” meaning a complete response (CR) or partial response (PR) to treatment...